“The proceeds from the capital raise together with the 2021 R&D rebate later in the year will put the company in a strong financial position to realise its strategy of becoming a world leader in exosome medicines through the commercialisation of its technology platforms and the development of new exosome medicine,” says Chief Executive Officer Dr Ian Dixon.
The 16.7 million new shares will be priced at 72c, three times last year’s 24c level, as the world wakes up to the therapeutic potential of exosomes.
Access the full Stockhead article here.